Precigen (PGEN) to Release Quarterly Earnings on Wednesday

Key Points

• Precigen (PGEN) is set to announce its Q2 2025 earnings on August 13th, with expectations of a loss of ($0.14) per share and revenue of $0.67 million.
• In the last quarter, Precigen reported a smaller loss than analysts anticipated, with earnings at ($0.07) per share and revenues significantly exceeding estimates at $1.34 million.
• Institutional investors have been active, with Strs Ohio purchasing a new position and AQR Capital Management increasing its stake by 216.9% during the first quarter.

Precigen (NASDAQ:PGEN - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect Precigen to post earnings of ($0.14) per share and revenue of $0.67 million for the quarter.

Precigen (NASDAQ:PGEN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Precigen had a negative net margin of 3,728.87% and a negative return on equity of 279.20%. The firm had revenue of $1.34 million for the quarter, compared to analyst estimates of $0.50 million. On average, analysts expect Precigen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Stock Performance

Shares of PGEN stock traded down $0.10 on Friday, hitting $1.78. 1,904,616 shares of the company's stock traded hands, compared to its average volume of 1,999,315. Precigen has a one year low of $0.65 and a one year high of $2.17. The company's fifty day simple moving average is $1.60 and its 200 day simple moving average is $1.56. The stock has a market capitalization of $525.42 million, a price-to-earnings ratio of -3.18 and a beta of 1.87.

Institutional Investors Weigh In On Precigen

Several hedge funds have recently bought and sold shares of the business. Strs Ohio purchased a new position in Precigen in the first quarter worth about $70,000. AQR Capital Management LLC raised its holdings in Precigen by 216.9% in the first quarter. AQR Capital Management LLC now owns 63,179 shares of the biotechnology company's stock worth $94,000 after buying an additional 43,245 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Precigen by 12.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 9,043 shares during the last quarter. Creative Planning raised its holdings in shares of Precigen by 127.8% during the second quarter. Creative Planning now owns 94,291 shares of the biotechnology company's stock valued at $134,000 after purchasing an additional 52,901 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Precigen by 7.7% during the second quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company's stock valued at $5,325,000 after purchasing an additional 269,580 shares during the last quarter. Institutional investors own 33.51% of the company's stock.

Analyst Upgrades and Downgrades

PGEN has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Precigen in a report on Thursday, May 15th. Wall Street Zen raised shares of Precigen from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $6.00 target price on shares of Precigen in a research note on Thursday, June 12th.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.